Crohn's Disease
VIDEO: Multimodal care, ‘aggressive’ medical treatment a must for perianal Crohn’s disease
In this Healio video exclusive, Miguel Regueiro, MD, shares highlights from his presentation at the GUILD Conference, where he discussed the importance of early, multimodal intervention in perianal fistulizing Crohn’s disease.
Shared decision-making for IBD treatment should be ‘patient centric’, evidence-based
LAS VEGAS — A presenter at the Crohn’s & Colitis Congress highlighted tips for successful decision-making with patients with inflammatory bowel disease, including how to approach conversations about the benefits and risks of treatments.
Infliximab levels above 6.9 mg/L at week 14 predict sustained remission in pediatric IBD
Infliximab concentrations above 6.9 mg/L at 14 weeks after initiation of treatment predicted sustained remission between 26 and 52 weeks in children with inflammatory bowel disease, according to researchers in the Netherlands.
Prebiotic inulin causes ‘beneficial changes’ in microbiome of children with IBD
LAS VEGAS — Supplementation with prebiotic oligofructose-enriched inulin resulted in short-term microbiome changes as early as 4 weeks among children with inflammatory bowel disease, according to a presenter at Crohn’s & Colitis Congress.
Depression ‘stronger predictor’ of fatigue in IBD vs. self-reported disease activity
LAS VEGAS — Depression strongly correlated with most fatigue subtypes, especially mental fatigue, among patients with inflammatory bowel disease, according to a presentation at the Crohn’s & Colitis Congress.
VIDEO: ‘Promising avenues of research’ may optimize IBD monitoring, address challenges
LAS VEGAS — In a Healio exclusive, Kelly Cushing-Damm, MD, MSCI, discusses how emerging monitoring strategies for inflammatory bowel disease, including telemedicine and artificial intelligence, may benefit both the patient and the practice.
Anti-TNF therapy significantly improves growth disturbances in pediatric Crohn’s
LAS VEGAS — Although a substantial proportion of children with Crohn’s disease had growth disturbances at initiation of anti-tumor necrosis factor therapy, “significant improvement” was noted up to 24 months after treatment, data showed.
VIDEO: ‘Presentation really matters’ when advising patients to work with IBD dietitian
LAS VEGAS — In a Healio video exclusive, Stacey Collins, MA, RDN/LD, highlights the importance of working with dietitians who specialize in inflammatory bowel disease and underscores their role on a patient’s care team.
The average cost of inflammatory bowel disease care neared $16,000 per patient in 2019
LAS VEGAS — The cost associated with treating inflammatory bowel disease “significantly increased” from 2009 to 2019 and was largely attributed to the annual cost of biologics, a presenter reported at the Crohn’s & Colitis Congress.
‘Perianal fistulas are preventable’ in pediatric Crohn’s with early anti-TNF therapy
LAS VEGAS — Early treatment with tumor necrosis antagonist was linked to 79% reduced odds of patients with pediatric Crohn’s disease developing perianal fistulizing complications, noted a presenter at the Crohn’s & Colitis Congress.